Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects

NCT03502954 is registered in ClinicalTrials.gov with Affibody as lead sponsor.

NCT NCT03502954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
Lead sponsor
Affibody
Phase
Phase 1
Overall status
Terminated
Start date
February 26, 2018
Completion date
March 20, 2020
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers